Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Azithromycin

FDA-approved product (capsule, oral), marketed as Azasite, Azithromycin, Zithromax and 1 more.

Registered studies
50+
Lab records
20
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Azithromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Cervicitis
  • Chronic bronchitis
  • Chronic obstructive pulmonary disease
  • Cystic fibrosis
  • Eye infection
  • HIV infection
  • Infection
  • Infectious otitis media
  • Otitis media
  • Pelvic Inflammatory Disease
  • Pharyngitis
  • Pneumonia
  • Recurrent tonsillitis
  • Sinusitis
  • and 2 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Macrolides; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01FA10; WHO ATC S01AA26

Repurposing investigation

Azithromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli89.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae88.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 7 of 9 lab records
  • E. coli: measured active in 3 of 3 lab records
  • K. pneumoniae: measured active in 8 of 8 lab records
Open Azithromycin in ChEMBL Registered studies below
Show the 20 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Azithromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Adverse Events Related to Treatments Used Against Coronavirus Disease 2019

    NCT04314817 · start 2020-03-17

    Registered record
    Registry ID
    NCT04314817
    Conditions
    Coronavirus; Iatrogenic Disease; Acute Kidney Injury; ARDS, Human
    Interventions
    Any drug used to treat Covid-19
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-03-17
    Completion
    2023-01-01
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus; Iatrogenic Disease; Acute Kidney Injury; ARDS, Human
    InterventionAny drug used to treat Covid-19
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19

    NCT04390152 · start 2020-01-13

    Registered record
    Registry ID
    NCT04390152
    Conditions
    Acute Respiratory Distress Syndrome
    Interventions
    Wharton's jelly derived Mesenchymal stem cells.; Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2020-01-13
    Completion
    2022-03-03
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Respiratory Distress Syndrome
    InterventionWharton's jelly derived Mesenchymal stem cells.; Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Azithromycin for Meibomian Gland Disease

    NCT03953118 · start 2019-09-01

    Registered record
    Registry ID
    NCT03953118
    Conditions
    Dry Eye; Neuropathic Eye Pain; Ocular Microbiome; Depression, Anxiety
    Interventions
    Azithromycin Oral Product; Placebo Oral
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-09-01
    Completion
    2021-07-01
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye; Neuropathic Eye Pain; Ocular Microbiome; Depression, Anxiety
    InterventionAzithromycin Oral Product; Placebo Oral
    PhasePhase 4
    Registry statusTerminated

  • Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

    NCT04047849 · start 2019-08-28

    Registered record
    Registry ID
    NCT04047849
    Conditions
    Rupture of Membranes; Delayed Delivery (Following Spontaneous Rupture); Rupture of Membranes; Premature; Rupture of Membranes; Premature, Affecting Fetus; Preterm Birth; Preterm PROM (Pregnancy); Preterm Labor
    Interventions
    Antibiotics, oral Azithromycin and oral Amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2019-08-28
    Completion
    2021-07-01
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRupture of Membranes; Delayed Delivery (Following Spontaneous Rupture); Rupture of Membranes; Premature +5 more
    InterventionAntibiotics, oral Azithromycin and oral Amoxicillin
    PhasePhase 4
    Registry statusRecruiting

  • Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial

    NCT03925480 · start 2019-07-01

    Registered record
    Registry ID
    NCT03925480
    Conditions
    Bacterial Infections
    Interventions
    Azithromycin 500 mg Oral Tablet x 4; Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-07-01
    Completion
    2023-02-28
    Enrolment
    2,110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionAzithromycin 500 mg Oral Tablet x 4; Matching Placebo
    PhasePhase 3
    Registry statusCompleted

  • Fluoroquinolone Associated Disability

    NCT03535558 · start 2018-05-17

    Registered record
    Registry ID
    NCT03535558
    Conditions
    Bronchitis; Sinusitis; Urinary Tract Infections
    Interventions
    Fluoroquinolone (FQ); Azithromycin (AZ); Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-05-17
    Completion
    2018-12-31
    Enrolment
    239,306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchitis; Sinusitis; Urinary Tract Infections
    InterventionFluoroquinolone (FQ); Azithromycin (AZ); Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
    PhaseNot recorded
    Registry statusCompleted

  • Anti-chlamydophila Antibiotic Combination Therapy in the Treatment of Patients With Coronary Heart Disease

    NCT03618108 · start 2018-04-04

    Registered record
    Registry ID
    NCT03618108
    Conditions
    Coronary Heart Disease; Chlamydophila Pneumoniae Infections
    Interventions
    Doxycycline Capsule; Azithromycin Capsule; Rifabutin Oral Capsule; Placebo oral capsule; Placebo Oral Tablet; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-04-04
    Completion
    2020-11-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Heart Disease; Chlamydophila Pneumoniae Infections
    InterventionDoxycycline Capsule; Azithromycin Capsule; Rifabutin Oral Capsule; Placebo oral capsule +2 more
    PhasePhase 2
    Registry statusTerminated

  • Early Life Interventions for Childhood Growth and Development In Tanzania

    NCT03268902 · start 2017-09-05

    Registered record
    Registry ID
    NCT03268902
    Conditions
    Malnutrition; Stunting; Cognitive Development; Enteric Pathogens
    Interventions
    Azithromycin Oral Liquid Product; Nitazoxanide Oral Suspension; Nicotinamide; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2017-09-05
    Completion
    2020-03-26
    Enrolment
    1,188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalnutrition; Stunting; Cognitive Development; Enteric Pathogens
    InterventionAzithromycin Oral Liquid Product; Nitazoxanide Oral Suspension; Nicotinamide; Placebos
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients

    NCT02527005 · start 2015-09

    Registered record
    Registry ID
    NCT02527005
    Conditions
    Malaria; Pregnant; HIV
    Interventions
    Sulphadoxine-pyrimethamine; Azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-09
    Completion
    2016-08
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Pregnant; HIV
    InterventionSulphadoxine-pyrimethamine; Azithromycin
    PhasePhase 1
    Registry statusCompleted

  • The Efficacy of Azithromycin in Treating Children With Non Cystic Fibrosis Bronchiectasis

    NCT02531984 · start 2015-08

    Registered record
    Registry ID
    NCT02531984
    Conditions
    Non Cystic Fibrosis Bronchiectasis in Children
    Interventions
    Azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-08
    Completion
    2018-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Cystic Fibrosis Bronchiectasis in Children
    InterventionAzithromycin
    PhasePhase 3
    Registry statusUnknown

  • Efficacy of Oral Probiotic and Antibiotic Administration in Patients With Chronic Periodontitis

    NCT02839408 · start 2015-06

    Registered record
    Registry ID
    NCT02839408
    Conditions
    Chronic Periodontitis
    Interventions
    Lactobacillus rhamnosus SP1; Azithromycin; Talc powder; Periodontal treatment Scaling and root planning
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-06
    Completion
    2017-03
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Periodontitis
    InterventionLactobacillus rhamnosus SP1; Azithromycin; Talc powder; Periodontal treatment Scaling and root planning
    PhasePhase 2
    Registry statusUnknown

  • Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis

    NCT02115516 · start 2014-04

    Registered record
    Registry ID
    NCT02115516
    Conditions
    Malaria; Plasmodium Falciparum Malaria
    Interventions
    PfSPZ Challenge; 0.9% Sodium Chloride (Placebo)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-04
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Plasmodium Falciparum Malaria
    InterventionPfSPZ Challenge; 0.9% Sodium Chloride (Placebo)
    PhasePhase 1
    Registry statusCompleted

  • The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study

    NCT01949363 · start 2013-12

    Registered record
    Registry ID
    NCT01949363
    Conditions
    Gonorrhoea
    Interventions
    Cefixime
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-12
    Completion
    2015-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonorrhoea
    InterventionCefixime
    PhasePhase 1
    Registry statusCompleted

  • Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

    NCT04870138 · start 2013-03-10

    Registered record
    Registry ID
    NCT04870138
    Conditions
    Gonococcal Infection
    Interventions
    Azithromycin; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090 A26; Neisseria gonorrhoeae strain FA7527
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-03-10
    Completion
    2015-04-28
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonococcal Infection
    InterventionAzithromycin; Ceftriaxone; Ciprofloxacin; Neisseria gonorrhoeae strain FA1090 A26 +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women

    NCT02575755 · start 2012-10

    Registered record
    Registry ID
    NCT02575755
    Conditions
    Pregnancy; Infections, Plasmodia; Drug Kinetics; Clinical Efficacy
    Interventions
    Azithromycin plus piperaquine phosphate; Sulfadoxine-pyrimethamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-10
    Completion
    2016-10
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy; Infections, Plasmodia; Drug Kinetics; Clinical Efficacy
    InterventionAzithromycin plus piperaquine phosphate; Sulfadoxine-pyrimethamine
    PhasePhase 4
    Registry statusUnknown